Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Asset Writedowns and Impairment (2016 - 2024)

Historic Asset Writedowns and Impairment for Theravance Biopharma (TBPH) over the last 4 years, with Q3 2024 value amounting to $1.6 million.

  • Theravance Biopharma's Asset Writedowns and Impairment changed N/A to $1.6 million in Q3 2024 from the same period last year, while for Dec 2024 it was $4.6 million, marking a year-over-year change of. This contributed to the annual value of $4.5 million for FY2024, which is N/A changed from last year.
  • Per Theravance Biopharma's latest filing, its Asset Writedowns and Impairment stood at $1.6 million for Q3 2024.
  • Theravance Biopharma's Asset Writedowns and Impairment's 5-year high stood at $3.0 million during Q2 2024, with a 5-year trough of $1.6 million in Q3 2024.